Synergistic Effects of Herbal and Allopathic Medicines: A Decade of Clinical Evidence (2015–2025)

Kanupriya Choudhary, Mandeep Kaur, Naresh Singh Gill, Vishal Kumar Thakur*

Department of Pharmaceutical Sciences, Rayat Institute of Pharmacy, Lamrin Tech Skill University, Rupnagar, Punjab-India

*Correspondence: vishalkumarkumar7820@gmail.com

DOI: https://doi.org/10.71431/IJRPAS.2026.5705       

INTRODUCTION

Herbal medicine has been used for millennia across traditional systems such as Ayurveda, Traditional Chinese Medicine, and Unani, while allopathic (conventional biomedical) pharmacotherapy has dominated modern clinical practice since the twentieth century. Over the last decade, however, a substantial body of research has explored the concurrent, rational use of herbal constituents alongside conventional drugs an approach often termed integrative or allopolyherbal therapy. The underlying premise is that phytochemicals, acting through complementary or overlapping molecular pathways, may potentiate drug efficacy, reduce required drug dosage, mitigate treatment related toxicity, or overcome drug resistance. Synergism in this context refers to a combined therapeutic effect that is greater than the sum of the effects of the herb and drug administered individually, and it is mechanistically distinct from simple additive or antagonistic interactions [1]. Systematic analyses of herbal synergism have shown that a substantial proportion of documented cases are attributable to genuine multi ingredient molecular interactions rather than placebo response [1], lending biological plausibility to the integrative therapy paradigm. Clinical interest in herb drug combinations has expanded markedly in oncology, where hundreds of trials predominantly from Chinese investigators have examined herbal adjuncts to chemotherapy, largely targeting pharmacokinetic modulation of the cytotoxic drug or reduction of drug induced toxicity [2]. Parallel efforts in cardio metabolic and musculoskeletal disease have examined herbal adjuncts to antihypertensives, oral hypoglycemics, and NSAIDs, aiming to reduce the drug burden associated with chronic, long term pharmacotherapy [3].

This review examines clinical evidence accumulated over the past ten years (2015–2025) on selected, well studied herb drug combinations, summarizing study designs, outcomes, and proposed mechanisms of synergism, and critically appraising the strength and limitations of the existing evidence base.

Review Methodology

This narrative review synthesizes peer reviewed randomized controlled trials (RCTs), systematic reviews, and meta-analyses published between 2015 and 2025, identified through structured searches of Pub Med/MEDLINE, Science Direct, Cochrane Library, and Google Scholar. Search terms combined "herb drug interaction," "synergistic," "combination therapy," "clinical trial," and individual herb and drug names (e.g., curcumin, berberine, silymarin, ginger, garlic, Boswellia, green tea/EGCG). Priority was given to randomized, placebo or active controlled human trials and high quality systematic reviews/meta-analyses reporting clinical (not solely in vitro or animal) outcomes. Mechanistic and pharmacokinetic studies were incorporated to contextualize clinical findings.

Mechanistic Basis of Herb Drug Synergism

Proposed mechanisms of herb drug synergism fall broadly into four categories:

•     Pharmacokinetic modulation: herbal constituents alter absorption, metabolism (commonly via cytochrome P450 enzymes), or elimination of the co-administered drug, increasing bioavailability or prolonging systemic exposure.

•     Pharmacodynamic complementation: herb and drug act on convergent or parallel molecular targets/pathways (e.g., apoptosis, inflammation, vasodilation), amplifying the net therapeutic effect.

•     Toxicity mitigation: herbal antioxidant or hepatoprotective activity counteracts drug induced organ toxicity (e.g., hepatotoxicity, neurotoxicity), permitting continuation or dose maintenance of the conventional drug.

•     Resistance reversal: phytochemicals modulate efflux transporters (e.g., P-glycoprotein) or resistance associated gene expression, restoring sensitivity to drugs in previously resistant cells.

Network pharmacology analyses of documented herbal synergism cases found that multi ingredient molecular interaction explained the observed synergy in 27 of 39 reported cases with available ingredient level data [1], supporting a biological (rather than purely statistical or placebo driven) basis for many reported clinical effects.

Clinical Evidence by Herb Drug Combination

Curcumin with Cytotoxic Chemotherapy

Curcumin, the principal curcuminoid of turmeric (Curcuma longa), has been evaluated as an adjuvant across multiple chemotherapy regimens. In a randomized, double blind, placebo controlled trial of 150 women with advanced/metastatic breast cancer, intravenous curcumin combined with paclitaxel produced a significantly higher objective response rate than paclitaxel plus placebo, with the advantage widening among patients who completed treatment (61% vs. 38%; odds ratio 2.64, p<0.01), and curcumin was associated with reduced fatigue and preserved quality of life [4]. In metastatic colorectal cancer, a randomized phase IIa trial (CUFOX) combining oral curcumin with FOLFOX chemotherapy found the combination safe and tolerable, with an exploratory overall survival hazard ratio of 0.34 (95% CI 0.14–0.82, p=0.02) favouring the curcumin chemotherapy arm without worsening neurotoxicity or quality of life [5]. A phase I/IIa dose escalation study similarly demonstrated safety and tolerability of curcumin combined with FOLFOX in colorectal liver metastases [6], and bioavailability boosted curcuminoids combined with chemotherapy suppressed systemic inflammation and improved quality of life in patients with solid tumours in a randomized double blind trial [7].

Table 1 Clinical trials of curcumin combined with cytotoxic chemotherapy regimens

Berberine with Metformin and Other Antidiabetic Agents

Berberine, an isoquinoline alkaloid from Berberis species, has been the most extensively trailed herbal adjunct in type 2 diabetes mellitus (T2DM). A systematic review and meta analysis of 50 RCTs (4,150 participants) concluded that berberine significantly enhances glycemic control through synergistic mechanisms when combined with metformin or pioglitazone [8]. A dedicated meta analysis of berberine metformin co-therapy found significant reductions in fasting plasma glucose and glycatedhemoglobin (HbA1c) versus metformin alone [9]. In a 12 week randomized controlled trial, a nutraceutical combining berberine, hesperidin, and chromium picolinate as add on therapy to metformin lowered fasting blood glucose by 11.7% and HbA1c by 7.5% from baseline, both significantly greater than metformin alone (p<0.01) [10]. A separate double blind RCT of berberine plus fenugreek seed co-supplementation reported significant reductions in fasting insulin, HbA1c, and high sensitivity C-reactive protein compared with control [11], while a phase II RCT of berberineursodeoxycholate (a berberine salt) in patients with non alcoholic steatohepatitis and diabetes achieved significantly greater reduction in liver fat content and improved glycemic control versus placebo [12].

Table 2 Clinical evidence for berberine combined with conventional antidiabetic therapy

Ginger as an Adjuvant to Antiemetic Drug Regimens

Ginger (Zingiber officinale) has been trailed extensively as an adjunct to standard 5-HT₃ antagonist/corticosteroid antiemetic regimens for chemotherapy induced nausea and vomiting (CINV), sharing overlapping 5-HT₃ receptor antagonism with drugs such as ondansetron and granisetron [13]. A systematic review of 23 RCTs found consistent adjuvant benefit of ginger supplementation for CINV when added to standard antiemetic therapy [14]. A double blind, placebo controlled trial of 1.2 g/day standardized ginger extract added to standard antiemetic improved chemotherapy induced nausea related quality of life [16], and this was corroborated by a larger multicenter, double blind, placebo controlled randomized trial (N=103), which found that adjuvant ginger root powder produced clinically relevant improvements in quality of life, delayed nausea and vomiting, fatigue, and nutritional status compared with placebo added to standard antiemetics [15].

Table 3 Clinical trials of ginger as an adjuvant to standard antiemetic pharmacotherapy

Silymarin (Milk Thistle) with Antitubercular Drugs

Silymarin, the flavono lignan complex of milk thistle (Silybum marianum), has been studied as a hepatoprotective adjunct to first line anti-tubercular therapy, which is commonly associated with drug induced liver injury (anti-TB DILI). A meta-analysis of five RCTs (1,198 patients) found that silymarin significantly reduced the incidence of anti-TB DILI at 4 weeks of co-administration, although this protective effect was not sustained at 8 weeks, indicating short term rather than long term hepato protection [16]. Individual RCTs registered in this meta-analysis, including a dedicated Iranian trial evaluating hepatoprotective effects among patients undergoing tuberculosis treatment, supported a reduction in liver enzyme elevation with concurrent silymarin use [17]. Only minor adverse effects (nausea, abdominal discomfort, dizziness) were reported with silymarin co-administration, supporting its safety profile alongside anti-tubercular regimens [16].

Table 4 Clinical evidence for silymarin as a hepatoprotective adjunct to antitubercular chemotherapy

Garlic with Antihypertensive Drugs

Garlic (Allium sativum) and its organosulfur constituents (allicin, S-allylcysteine) have been evaluated as adjuncts to standard antihypertensive drugs, with proposed synergism at the level of nitric oxide mediated vasodilation and calcium channel modulation [18]. An open, randomized, parallel group study found that garlic extract combined with amlodipine produced a greater reduction in blood pressure than amlodipine alone in patients with mild to moderate essential hypertension [19], and comparable findings were reported for garlic tablets added to telmisartan, an angiotensin receptor blocker, which more effectively lowered systolic blood pressure than telmisartan monotherapy [20]. A randomized, triple blind, placebo controlled trial of an optimized aged garlic extract in patients with Grade I hypertension already on antihypertensive drug therapy found modest but statistically significant additional reductions in systolic (1.8 mmHg) and diastolic (1.5 mmHg) blood pressure, alongside increased nitric oxide bioavailability and reduced angiotensin converting enzyme (ACE) activity [21].

Table 5 Clinical trials of garlic extract combined with conventional antihypertensive drugs

Green Tea Catechins (EGCG) with Anticancer and Endocrine Therapy

Epigallocatechin-3-gallate (EGCG), the principal catechin of green tea, has demonstrated synergistic anticancer activity when combined with a range of chemotherapeutic and endocrine agents in preclinical and translational studies. Combined EGCG and anticancer drugs (including 5-fluorouracil, taxanes, and gefitinib) synergistically enhanced apoptosis related gene expression (GADD153) 10 to 15-fold compared with either agent alone in lung cancer cell models, a finding that has informed subsequent clinical translation efforts [22]. A systematic review of the interaction between green tea catechins and breast cancer endocrine therapy concluded that EGCG demonstrates a synergistic interaction with tamoxifen and raloxifene in both estrogen receptor positive and negative breast cancer models, supporting co-administration as a rational chemo preventive and adjuvant strategy [23]. EGCG was additionally found to down regulate P-glycoprotein and BCRP efflux transporters, restoring drug sensitivity in a tamoxifen resistant breast cancer cell line [24], and further studies have demonstrated synergistic cytotoxicity between EGCG and cisplatin or gemcitabine in biliary tract cancer models [25]. While robust randomized clinical (as opposed to cell-line/translational) data remain limited for this combination relative to curcumin or berberine, the convergence of mechanistic and epidemiological evidence supports continued clinical investigation [26].

Table 6 Evidence for green tea catechin (EGCG) synergism with anticancer and endocrine drugs

Boswellia serrata and Curcumin with NSAIDs in Osteoarthritis

Boswellic acids from Boswellia serrata gum resin, alone and combined with curcumin, have been studied as dose sparing adjuncts to NSAID therapy in knee osteoarthritis. A systematic review and meta-analysis reported that combining boswellic acids (notably AKBA) with NSAIDs enhanced anti-nociceptive effect and allowed reduction of NSAID therapeutic doses, thereby lowering the risk of gastrointestinal, renal, and cardiovascular adverse effects associated with long term NSAID use [27]. In a placebo controlled RCT of rheumatoid arthritis outpatients, Boswellia supplementation was associated with a numerically greater decline in concomitant NSAID use compared with placebo (5.8% vs. 3.1%) [28]. A randomized, placebo controlled, double blind, multicenter trial of Boswellia serrata combined with Apium graveolens (celery seed) extract in knee osteoarthritis reported a significant reduction in the need for analgesic (NSAID) medication compared with placebo, alongside reductions in multiple inflammatory and cartilage degradation biomarkers [29]. Separately, a two arm RCT combining Curcuma longa extract with diclofenac reported comparable benefit in pain and function to diclofenac alone, without added disadvantage, though the difference did not reach statistical significance [27].

Table 7 Clinical trials of Boswelliaserrata/curcumin combined with NSAID therapy in osteoarthritis.

Phytochemical Antibiotic Synergism (Antimicrobial Resistance Context)

Beyond chronic disease management, phytochemicals have been widely explored as adjuncts to conventional antibiotics to counter antimicrobial resistance (AMR). Reviews of ethno pharmacological and phytochemical literature note that many phytochemicals exhibit synergistic interactions both within complex plant extracts (the "entourage effect") and when combined with conventional antibiotics, thereby enhancing antimicrobial potential and mitigating resistance mechanisms [30]. Despite promising in vitro and preclinical data, translation into standardized, regulator approved clinical combination products remains limited by challenges in phytochemical standardization, bioavailability, and regulatory pathways.

Safety Considerations and Herb Drug Interaction Risks

While this review emphasizes beneficial synergistic combinations, herb drug interactions are not uniformly favourable, and the same pharmacokinetic mechanisms that enable synergism can also produce harmful interactions when unrecognized. Cytochrome P450 modulation is a recurrent theme, animal studies show that green tea catechins inhibit CYP3A-mediated metabolism of amlodipine, increasing its maximum plasma concentration and area under curve while prolonging its half-life. This interaction that could necessitate antihypertensive dose adjustment if untitrated in clinical practice. Clinicians should therefore distinguish deliberate, dose controlled, trial validated combination therapy from incidental, unsupervised concurrent use of herbal supplements and prescription drugs. Key safety principles include routine medication reconciliation that explicitly asks about herbal and dietary supplement use, awareness that standardization of herbal extracts varies substantially between commercial products, affecting reproducibility of clinical trial findings [18],  and recognition that vulnerable populations (hepatic or renal impairment, polypharmacy, pregnancy) warrant particular caution when combining herbal and conventional agents.

CONCLUSION

Clinical research over the past decade provides encouraging, though uneven, evidence that select herb drug combinations can produce genuine synergistic benefit. The strongest clinical evidence exists for curcumin combined with cytotoxic chemotherapy in breast and colorectal cancer, berberine combined with metformin in type 2 diabetes, ginger combined with standard antiemetics for chemotherapy induced nausea and vomiting, and Boswellia/curcumin combined with NSAIDs in knee osteoarthritis, where randomized controlled trials demonstrate improved efficacy, dose sparing, or reduced toxicity. Evidence for silymarin with antitubercular drugs and garlic with antihypertensive agents is supportive but shows time limited or modest effect sizes. Green tea catechin combinations remain predominantly supported by mechanistic and translational rather than large scale clinical trial data. Across all categories, methodological heterogeneity, inconsistent herbal standardization, and small trial sizes temper confidence in the magnitude of reported effects. Future progress in integrative pharmacotherapy will depend on rigorously standardized herbal formulations, adequately powered multicenter trials, and harmonized regulatory and pharmacovigilance frameworks to translate promising synergistic signals into safe, reproducible clinical practice.

REFERENCES

1.        Qian W, Zhang B, Gao M, Wang Y, Shen J, Liang D. Synergistic therapeutic actions of herbal ingredients and their mechanisms from molecular interaction and network perspectives. J Pharm Anal. 2025; 15(2): 101056.

2.         Hemaiswarya S, Prabhakar PP, Doble M. Clinical trials on synergistic herb-drug interactions. Springer. 2023: 251-263 .

3.        Shinde SA, Mali DP, Thorat VM, Walgude AD. Integrative approaches in hypertension management: a review of the combination of allopathic drugs and herbal medicines in drug delivery systems. Int J Drug Deliv Technol. 2025; 15(2): 825-838.

4.        Saghatelyan T, Tananyan A, Janoyan N, Tadevosyan A, Petrosyan H, Hovhannisyan A. Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: a comparative, randomized, double-blind, placebo-controlled clinical trial. Phytomedicine. 2020; 70: 153218.

5.        Howells LM, Iwuji COO, Irving GRB, Barber S, Walter H, Sidat Z. Curcumin combined with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial. J Nutr. 2019;149(7):1133-1139.

6.        James MI, Iwuji C, Irving G, Karmokar A, Higgins JA, Griffin-Teal N. Curcumin associated with FOLFOX chemotherapy is safe and tolerable in patients with metastatic colorectal cancer in a randomized phase IIa trial (CUFOX). BMC Cancer. 2015; 15: 559.

7.        Panahi Y, Saadat A, Beiraghdar F, Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial. Phytother Res. 2014; 28(10):1461-1467.

8.        Wang J, Bi C, Xi H, Wei F. Effects of administering berberine alone or in combination on type 2 diabetes mellitus: a systematic review and meta-analysis. Front Pharmacol. 2024 Nov 21; 15: 1455534.

9.        Wang L, Liu D, Wei G, Ge H. Berberine and Metformin in the Treatment of Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis of Randomized Clinical Trials. Health. 2021; 13: 1314-1329.

10.    Derosa G, D'Angelo A, Maffioli P. Effect of a new formulation of nutraceuticals as an add-on to metformin monotherapy for patients with type 2 diabetes and suboptimal glycemic control: a randomized controlled trial. Nutrients. 2021; 13(7): 2373.

11.    Nematollahi S, Pishdad GR, Zakerkish M, Namjoyan F, Ahmadi Angali K, Borazjani F. The effect of berberine and fenugreek seed co-supplementation on inflammatory factor, lipid and glycemic profile in patients with type 2 diabetes mellitus: a double-blind controlled randomized clinical trial. DiabetolMetabSyndr. 2022; 14: 120.

12.    Harrison SA, Gunn N, Neff GW, Kohli A, Liu L, Flyer A. A phase 2, proof of concept, randomised controlled trial of berberineursodeoxycholate in patients with presumed non alcoholic steatohepatitis and type 2 diabetes. Nat Commun. 2021; 12: 5503.

13.    Marx W, McCarthy AL, Ried K, McKavanagh D, Vitetta L, Sali A. The effect of a standardized ginger extract on chemotherapy induced nausea related quality of life in patients undergoing moderately or highly emetogenic chemotherapy: a double blind, randomized, placebo controlled trial. Nutrients. 2017; 9(8): 867.

14.    Choi J, Lee J, Kim K, Choi HK, Lee SA, Lee HJ. Effects of ginger intake on chemotherapy-induced nausea and vomiting: a systematic review of randomized clinical trials. Nutrients. 2022; 14(23): 4982.

15.    Crichton M, Marshall S, Isenring E, Lohning A, McCarthy AL, Molassiotis A. Effect of a standardized ginger root powder regimen on chemotherapy induced nausea and vomiting: a multicenter, double-blind, placebo-controlled randomized trial. J Acad Nutr Diet. 2024; 124(3): 313-330.

16.    Tao L, Qu X, Zhang Y, Song Y, Zhang SX. Prophylactic therapy of silymarin (milk thistle) on antituberculosis drug-induced liver injury: a meta-analysis of randomized controlled trials. Can J Gastroenterol Hepatol. 2019; 2019:3192351.

17.    Marjani M, Baghaei P, KazempourDizaji M, GorjiBayani P, Fahimi F, Tabarsi P. Evaluation of hepatoprotective effect of silymarin among under treatment tuberculosis patients: a randomized clinical trial. Iran J Pharm Res. 2016; 15(1): 247-252.

18.    Nowak A, Kojder K, Zielonka-Brzezicka J, Wrobel J, Bosiacki M, Fabianska M. Cardiovascular effects of herbal products and their interaction with antihypertensive drugs comprehensive review. Nutrients. 2024; 16(11): 1785.

19.    Satyanand V , Reddy CB, RamaMohan P, Kumar MJ, Narayanaswamy D, Seelam A, Krishnan  R, Rao PS.  Effects of garlic extract (Allium sativum) in combination with amlodipine in mild to moderate essential hypertensive patients: an open randomized parallel group study. J. Pharm. Res. Dev. 2013; 2(4): 181-188.

20.    Mustafa RA, Ayami H, Halimi M. Effects of garlic tablet (GARLET) in combination with telmisartan on high blood pressure. InaJBCS  2024; 56(3): 245-253.

21.    Gomez Rico I, Rosich Medina A, Garcia Perez P, Marin Royo G, Fernandez Alfonso MS, Rodriguez Rodríguez R. Antihypertensive effects of an optimized aged garlic extract in subjects with grade I hypertension and antihypertensive drug therapy: a randomized, triple-blind controlled trial. Nutrients. 2023; 15(17): 3861.

22.    Suganuma M, Saha A, Fujiki H. New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci. 2011; 102(2): 317-323.

23.    Braal CL, Jongbloed EM, Wilting SM, Mathijssen RHJ, Koolen SLW, Jager A. Interaction of green tea catechins with breast cancer endocrine treatment: a systematic review. Pharmacology. 2019; 104(5-6): 246-253.

24.    Farabegoli F, Papi A, Bartolini G, Ostan R, Orlandi M. (−)-Epigallocatechin-3-gallate downregulatesPg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine. 2010; 17(5): 356-362.

25.    Kutschera M, Wilfinger J, Fuchs D, Ausserlechner MJ, Obexer P, Berger W. The green tea catechinepigallocatechingallate induces cell cycle arrest and shows potential synergism with cisplatin in biliary tract cancer cells. BMC Complement Altern Med. 2015; 15: 83.

26.    Fujiki H, Sueoka E, Watanabe T, Suganuma M. Synergistic enhancement of anticancer effects on numerous human cancer cell lines treated with the combination of EGCG, other green tea catechins, and anticancer compounds. J Cancer Res Clin Oncol. 2015; 141(9): 1511-1522.

27.    Yu C, Zhang P, Lou L, Wang Y. Efficacy of curcumin and Boswellia for knee osteoarthritis: systematic review and meta-analysis. Front Pharmacol. 2020; 11: 590.

28.    Sander O, Herborn G, Rau R. Is H15 (resin extract of Boswellia serrata, 'incense') a useful supplement to established drug therapy of chronic polyarthritis? Results of a double-blind pilot study. Z Rheumatol. 1998; 57(1): 11-6.

29.     Vaidya N, Agarwal R, Dipankar DG, Patkar H, Ganu G, Nagore D, Godse C, Mehta A, Mehta D, Nair S. Efficacy and Safety of Boswellia serrata and Apium graveolens L. Extract Against Knee Osteoarthritis and Cartilage Degeneration: A Randomized, Double-blind, Multicenter, Placebo-Controlled Clinical Trial. Pharm Res. 2025; 42(2): 249-269.

30.    Parveen A, Parveen B, Parveen R, Ahmad S. Challenges and guidelines for clinical trial of herbal drugs. J Pharm Bioallied Sci. 2015; 7(4): 329-333.